Oxford has entered into an R&D collaboration with Microsoft to improve the yield and quality of next-generation gene therapy vectors using the cloud and machine learning. The partnership involves developing next-generation manufacturing technologies with the expertise of Oxford Biomedica researchers. It is initially for a two-year period and may be extended by either party. Oxford will use Microsoft Azure intelligent cloud platform for the analysis of large data sets.
Oxford will leverage Microsoft’s cloud computing and machine learning capabilities to develop in silico models and novel algorithms to help advance the next generation of cell and gene delivery technology.
Jason Slingsby, Oxford Biomedica’s Chief Business Officer, said: “The collaboration with Microsoft Research will harness our rich data resources to offer greater insights into the biological processes required to enhance quality and optimise yields of lentiviral vectors.”